

## Review Form 1.6

Journal Name:	<a href="#">Journal of Pharmaceutical Research International</a>
Manuscript Number:	Ms_JPRI_80149
Title of the Manuscript:	Drug Induced Anaphylactic Reaction and Electrolyte Imbalance by Amphotericin B Emulsion : A Case Report
Type of the Article	Case Study

### **General guideline for Peer Review process:**

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

<https://www.journaljpri.com/index.php/JPRI/editorial-policy>

**Review Form 1.6**

**PART 1: Review Comments**

	<b>Reviewer's comment</b>	<b>Author's comment</b> (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<b>Compulsory</b> REVISION comments	<ol style="list-style-type: none"> <li>1. In Abstract author has mentioned various side-effects of drug Amphotericin B, but has not included the its most common and toxic effect i.e nephrotoxicity</li> <li>2. Amphotericin B emulsion was administered by infusion as mentioned in abstract, the name of emulsion should be mentioned (marketed name) as only liposomal or lyophilized powder of Amphotericin is mostly used</li> <li>3. The ethical approval number should be provided.</li> <li>4. The word conclusions should be corrected as conclusion</li> <li>5. The reference no. 14 is numbered before 12, references should be numbered again in sequence</li> <li>6. All the grammatical errors should be corrected. Introduction 2<sup>nd</sup> para "Currently, three lipid Liposomal..... are commercially available formulations" should be written as " Currently, three lipid based formulations of Amphotericin B namely Liposomal (AmBisome, NeXstar Pharmaceuticals/Fujisawa, San Dimas, CA), colloidal dispersion (ABCD, Amphocil, Sequus Pharmaceuticals, Menlo Park, CA), and lipid complex are available commercially"</li> <li>7. The name of drug used to be uniform throughout the content. It should be "Amphotericin B"</li> <li>8. Discussion should be presented more clearly as this can be helpful for patients suffering from such conditions</li> <li>9. Under case presentation the word "debridement" should be changed</li> <li>10. Under case presentation, author has mentioned " administered 200mg of amphotericin b in 250ml of 5% dextrose and infused for 3-4 hours (60mg/hr)". Pure dure cannot be used, then which 200mg powder was used</li> <li>11. In title emulsion word should not be used as it cannot be emulsion because no emulsion based intravenous formulation of Amphotericin B is available commercially</li> </ol>	
<b>Minor</b> REVISION comments		
<b>Optional/General</b> comments		

## Review Form 1.6

### **PART 2:**

	<b>Reviewer's comment</b>	<b>Author's comment</b> <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
<b>Are there ethical issues in this manuscript?</b>	<i>(If yes, Kindly please write down the ethical issues here in details)</i> Yes. This study is on patient. So, consent and ethical approval number should be provided	

### **Reviewer Details:**

Name:	<b>Lakhvir Kaur</b>
Department, University & Country	<b>Khalsa College of Pharmacy, India</b>